Tumor desmoide de la pared torácico-abdominal. Caracterización con PET-TAC con 18F-fluorodesoxiglucosa y correlación con resonancia magnética y gammagrafía ósea. Revisión de la literatura

Ramos-Font, C.; Chinchilla, A. Santiago; Aguirre, A.C. Rebollo; Fernández, Antonio Rodríguez; Benítez, Antonio Medina; Elvira, J.M. Llamas

doi:10.1016/s0212-6982(09)70700-1

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, documented SUV changes under treatment with imatinib were relatively small. We could show that PET monitoring of desmoid patients under treatment with imatinib may be used to determine whether patients benefit from imatinib therapy or not in the lack of an adequate CT and/or MRI imaging [26]. In particular the initial average SUV1 and SUV1 max data seem to be candidates for a response prediction and may act as surrogate markers.…”

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib

Kasper

Dimitrakopoulou-Strauß

Pilz

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib. The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily. Patients were examined using PET prior to onset of therapy and during treatment. Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI). Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD. A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV. Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD. The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively. This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued.

show abstract

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib

Kasper

Dimitrakopoulou-Strauß

Pilz

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Kasper

Dimitrakopoulou-Strauß

Strauss

et al. 2010

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Diagnostic imaging and CEUS findings in a rare case of Desmoid-type fibromatosis. A case report

Valentino¹,

Liberatore

Maghella

et al. 2018

J Ultrasound

View full text Add to dashboard Cite

Desmoid-type fibromatosis (DF), also known as aggressive fibromatosis, is a locally aggressive benign fibroblastic neoplasm that can infiltrate or recur but cannot metastasize. It is rare, with an estimated annual incidence of two to four new cases per million people. Most DFs occur sporadically, but it may also be associated with the hereditary syndrome familial adenomatous polyposis. Treatment is necessary when the disease is symptomatic, especially in case of compression of critical structures. When possible, surgical resection is the treatment of choice; however, recurrence is common. Due to the high rate of recurrence, imaging plays an important role not only in diagnosis, but also in the management of DF. Although there are a number of studies describing CT and MRI findings of DF, there is no description of contrast-enhanced ultrasound findings.

show abstract

Tumor desmoide de la pared torácico-abdominal. Caracterización con PET-TAC con 18F-fluorodesoxiglucosa y correlación con resonancia magnética y gammagrafía ósea. Revisión de la literatura

Cited by 4 publications

References 19 publications

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

Diagnostic imaging and CEUS findings in a rare case of Desmoid-type fibromatosis. A case report

Contact Info

Product

Resources

About